MedTrace Logo

Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

NCT04562285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 829

Last updated 2025-12-03

No results posted yet for this study

Summary

The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Serologic immunoassays to SARS-CoV-2 antibodies

Detect and characterize antibodies to SARS-CoV-2

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2021-05-28
Completion
2024-06-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562285 on ClinicalTrials.gov